Physician profile
Husam Bahgat Shitia
NPI 1972604528
$6,755.92
in general payments reported to CMS, 2019-2025
24 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what 93% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $304 · 2021: $623 · 2022: $838 · 2023: $1,031 · 2024: $1,961 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,816.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,245.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,741.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $437.44 | 2019-2025 | |
| Exact Sciences Corporation | $421.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $351.95 | 2022-2024 | Ubrelvy, Qulipta |
| Pfizer INC. | $299.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $251.18 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $173.43 | 2022-2024 | Mounjaro, Trulicity |
| Bausch Health US, LLC | $172.16 | 2019-2025 | Wellbutrin, Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.17 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $103.30 | 2024-2025 | Orladeyo |
| Sanofi Pasteur INC. | $98.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2020-2022 | |
| Novo Nordisk INC | $39.22 | 2025 | Wegovy |
| Genentech USA, INC. | $35.93 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.62 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $20.40 | 2024 | Quviviq |
| Corcept Therapeutics | $19.79 | 2024 | Korlym |
| Sumitomo Pharma America, INC. | $19.68 | 2025 | Gemtesa |
| Dexcom, INC. | $19.03 | 2025 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $18.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2021 | |
| Medtronic Vascular, INC. | $14.99 | 2020 | |
| Seqirus USA INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Shitia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.